To earn CME related to this news article, click here. January 21, 2009 (Rochester, Minnesota) — Diastolic dysfunction is independently and strongly related to reduced exercise capacity, a new ...

Cardiomyopathy is the leading cause of mortality in patients with DMD. Compared with their healthy counterparts, patients with DMD — including those with preserved left ventricular ejection fraction ...

Hypertension is believed to be the single greatest factor influencing the development of heart failure, particularly heart failure with preserved ejection fraction, also known as diastolic heart ...

Diabetes mellitus is recognised as a major risk factor for heart failure, in which diastolic dysfunction frequently precedes overt systolic impairment. In this context, the term describes an ...

Diastolic dysfunction arises when the left ventricle fails to relax or fill normally during diastole, often despite a preserved ejection fraction. This impairment leads to elevated filling pressures, ...

Nocturnal hypertension is an important predictor of the progression of left ventricular diastolic dysfunction in patients with diabetes without HF. An important predictor for the progression of left ...

Please provide your email address to receive an email when new articles are posted on . An AI algorithm for detection of grade 3 diastolic dysfunction received a breakthrough device designation from ...

While cardiovascular disease (CVD) is more common in young men than in young women, the risk of CVD increases for postmenopausal women, making them nearly as susceptible as men. Menopause typically ...

A University of Alberta pharmacology researcher has discovered that a new experimental anti-obesity drug improves diastolic heart function in mice with type 2 diabetes independent of its weight loss ...

Orchestra BioMed Holdings, Inc. announced promising echocardiographic data regarding atrioventricular interval modulation (AVIM) therapy's impact on patients with diastolic dysfunction at the THT 2025 ...

Researchers from Edgewise Therapeutics Inc. presented preclinical data for the cardiac sarcomere modulator, EDG-7500, which is being developed for the treatment of hypertrophic cardiomyopathy (HCM) ...